Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: A randomized controlled trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

This study aimed to compare the effect of a Standard nutritional supplement with an Enhanced nutritional supplement combining three nutriceuticals on functional outcomes in ambulatory boys with Duchenne muscular dystrophy (DMD).

Who Took Part

PubMed tags the participants as men only.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

In the crossover set-up each of the participants took both Copper (Supplement) and the comparison in turn, acting as their own control.

A 50-week double blinded, randomized, controlled crossover trial was conducted in four Australian neuromuscular centres.

Primary outcome measures were 6-min walk distance (6MWD) and community ambulation (StepWatch™ Activity Monitoring).

Secondary outcome measures included body composition and quality of life.

Serum 25-hydroxyvitamin D was measured.

What Was Measured

The subject headings attached to it are Australia, Body Composition, Dietary Supplements, Functional Status, Minimal Clinically Important Difference, Muscular Dystrophy, Duchenne and Nutritional Physiological Phenomena.

The authors tagged it with the keywords Creatine monohydrate, Diet supplementation, Duchenne muscular dystrophy, Glutamine, HMB and Whey protein.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Copper (Supplement).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.